Sells next-generation sequencing sample-preparation tools to diagnostic and research organizations, and synthetic DNA products and antibody-discovery services to biotech, pharmaceutical and industrial customers.
10-K for FY2025, filed Nov 17, 2025Our NGS products are primarily used within diagnostic tests for various indications including rare disease, SARS-CoV-2 and cancer through…View ↗
Synthetic genes are manufactured strands of DNA. Customers (biotech, pharma, industrial chemical, agricultural companies as well as…View ↗
Modern therapeutic targets are increasing in complexity and traditional, single modality platforms are no longer sufficient on their own.…View ↗
Customers pay for synthetic genes, oligo pools, DNA libraries and NGS tools when products ship. Biopharma customers may pay upfront and at milestones, for development work as it progresses, and through license payments.
10-K for FY2025, filed Nov 17, 2025
10-K for FY2025, filed Nov 17, 2025
FY2025 revenue by product or service ↗$376.6M
10-K for FY2025, filed Nov 17, 2025
$376.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Synthetic genes
Sold outright
10-K for FY2025, filed Nov 17, 2025 |
30%
FY2022: 30%
|
Synthetic genes, FY2025
$113.6M Sources
|
Sold outright |
|
Oligo pools
Sold outright
|
5.4%
FY2022: 6.1%
|
Oligo pools, FY2025
$20.2M Sources
|
Sold outright |
|
DNA libraries
Sold outright
|
3.0%
FY2022: 3.0%
|
DNA libraries, FY2025
$11.2M Sources
|
Sold outright |
|
Antibody discovery
Mix
|
6.2%
FY2022: 12%
|
Antibody discovery, FY2025
$23.5M Sources
|
Mix |
|
NGS tools
Sold outright
10-K for FY2025, filed Nov 17, 2025 |
55%
FY2022: 49%
|
NGS tools, FY2025
$208.1M Sources
|
Sold outright |
Research and commercial customers across life sciences, industry and agriculture buy synthetic biology products and NGS tools, including diagnostic organizations and hospitals. Product sales use direct sales, e-commerce and distributors; biopharma partners work with business-development and sales representatives.
10-K for FY2025, filed Nov 17, 2025Synthetic genes are manufactured strands of DNA. Customers (biotech, pharma, industrial chemical, agricultural companies as well as…View ↗
Our NGS products are primarily used within diagnostic tests for various indications including rare disease, SARS-CoV-2 and cancer through…View ↗
We have built a versatile and scalable commercial platform that enables us to reach a diverse customer base that we estimate consists of…View ↗
We sell our products through a worldwide commercial organization that includes direct sales personnel, commercial consultants in Europe and…View ↗
We provide end-to-end services, whereby customers can choose to design and/or purchase libraries, or select various discovery platforms for…View ↗
No. It lost $77.7M in FY2025.
10-Q for Q3 FY2026, filed Aug 3, 2026
−$35.1MView ↗
10-Q for Q3 FY2026, filed Aug 3, 2026
Open tableView ↗
8-K, filed Nov 12, 2026
— Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at the midpoint —View ↗
Growing. Revenue grew 2.8x in 4 years, from $132.3M in FY2021 to $376.6M in FY2025, about 30% a year.
DNA data storage
The earlier report described DNA data storage as an application under development and a market opportunity; the latest report says Twist sold the business to Atlas, moving it outside the company's operations.
10-K for FY2022, filed Nov 28, 2022 10-K for FY2025, filed Nov 17, 2025We sold our DNA data storage business to Atlas Data Storage, Inc. ("Atlas"), a newly formed company, that will focus solely on DNA data…View ↗
Biopharma services
The earlier report framed biological drug discovery as a portfolio expansion opportunity alongside DNA and NGS products; the latest report includes biopharma services for antibody discovery, optimization and development among current revenue sources.
10-K for FY2022, filed Nov 28, 2022 10-K for FY2025, filed Nov 17, 2025We currently generate revenue through our synthetic biology and NGS tools product lines. In addition, we are leveraging our platform to…View ↗
We currently generate revenue through our synthetic biology and NGS tools product lines as well as biopharma services for antibody…View ↗
Competes with GenScript Biotech, Azenta Life Sciences, Integrated DNA Technologies, DNA 2.0, Thermo Fisher Scientific, Eurofins Genomics, OriGene Technologies, Elegen, Ansa Biotechnologies, Telesis Bio, Illumina, Roche Holding, New England Bioloabs, Watchmaker Genomics, Agilent Technologies, Curia Global, Genovac, FairJourney Biologics, IONTAS, and Adimab
10-K for FY2025, filed Nov 17, 2025We face competition from a broad range of providers of core synthetic biology products such as GenScript Biotech Corporation, GENEWIZ…View ↗
Loading...